We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+139.15%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$729M
AUM Growth
+$208M
Cap. Flow
+$91.8M
Cap. Flow %
12.61%
Top 10 Hldgs %
81.82%
Holding
47
New
5
Increased
2
Reduced
8
Closed
4

Top Buys

Rank Stock Value
1
SEPN
Septerna Inc
SEPN
+$65.5M
2
UPB
Upstream Bio Inc
UPB
+$49.5M
3
NGNE icon
Neurogene
NGNE
+$16.7M
4
OKUR
OnKure Therapeutics
OKUR
+$12.5M
5
PVLA
Palvella Therapeutics
PVLA
+$10.7M

Top Sells

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$38.3M
2
ACLX
Arcellx
ACLX
+$8.64M
3
LENZ
LENZ Therapeutics
LENZ
+$6.75M
4
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$3.84M
5
IOBT
IO Biotech
IOBT
+$3.82M

Sector Composition

Rank Sector Weight
1 Healthcare 99.03%
2 Financials 0.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRK icon
1
Scholar Rock
SRRK
$5.71B
$243M 33.3%
5,612,896
-1,175,713
-17% -$38.3M
CRGX
2
DELISTED
CARGO Therapeutics
CRGX
$63.7M 8.74%
4,415,689
– –
SEPN
3
Septerna Inc
SEPN
$1.49B
$63.4M 8.7%
+2,768,520
New +$65.5M
MLYS icon
4
Mineralys Therapeutics
MLYS
$2.35B
$62.5M 8.57%
5,074,916
– –
NGNE icon
5
Neurogene
NGNE
$696M
$39.3M 5.39%
1,717,127
+449,337
+35% +$16.7M
UPB
6
Upstream Bio Inc
UPB
$349M
$36.4M 5%
+2,217,146
New +$49.5M
LENZ
7
LENZ Therapeutics
LENZ
$172M
$28.5M 3.91%
986,981
-221,492
-18% -$6.75M
ALMS
8
Alumis Inc
ALMS
$3.57B
$25.7M 3.52%
3,266,498
– –
ACLX
9
DELISTED
Arcellx
ACLX
$19.5M 2.67%
253,641
-100,000
-28% -$8.64M
ZYME icon
10
Zymeworks
ZYME
$1.68B
$14.6M 2.01%
1,000,000
– –
JSPR icon
11
Jasper Therapeutics
JSPR
$22.9M
$12.5M 1.72%
584,642
– –
AVDL
12
DELISTED
Avadel Pharmaceuticals
AVDL
$10.2M 1.4%
967,527
– –
RYTM icon
13
Rhythm Pharmaceuticals
RYTM
$7B
$9.66M 1.33%
172,647
– –
NKTX icon
14
Nkarta
NKTX
$162M
$9.38M 1.29%
3,768,035
– –
CTNM
15
Contineum Therapeutics
CTNM
$526M
$8.63M 1.18%
588,816
– –
PVLA
16
Palvella Therapeutics
PVLA
$1.98B
$8.15M 1.12%
+679,486
New +$10.7M
SLRN
17
DELISTED
ACELYRIN
SLRN
$7.92M 1.09%
2,523,022
– –
OKUR
18
OnKure Therapeutics
OKUR
$166M
$7.09M 0.97%
+824,155
New +$12.5M
CYPH
19
Cypherpunk Technologies Inc
CYPH
$66.2M
$7.02M 0.96%
2,442,352
– –
ABVX
20
Abivax
ABVX
$11B
$6.22M 0.85%
850,000
– –
ACRS icon
21
Aclaris Therapeutics
ACRS
$730M
$5.91M 0.81%
2,385,060
+1,688,889
+243% +$4.2M
GOSS icon
22
Gossamer Bio
GOSS
$66.5M
$5.55M 0.76%
6,130,268
– –
CLYM
23
Climb Bio
CLYM
$735M
$4.7M 0.64%
2,609,114
– –
VRNA
24
DELISTED
Verona Pharma
VRNA
$4.53M 0.62%
97,625
-97,600
-50% -$3.66M
INZY
25
DELISTED
Inozyme Pharma
INZY
$4.33M 0.59%
1,562,500
– –
1
2

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
GSIS
Global Strategic Investment Solutions Scottsdale, Arizona $1.03B AUM 16.75% 1-Year Est. Return
RIM
RW Investment Management Eagle, Idaho $1.03B AUM
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return

Samsara BioCapital's Q4 2024 Portfolio in Review

As of Q4 2024, Samsara BioCapital held 47 positions worth $729M, up 40% from $520M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Samsara BioCapital deployed $91.8M of net new capital in Q4 2024, opening 5 new positions and adding to 2 existing holdings. Its largest new stake was Septerna Inc: 2,768,520 shares worth $63.4M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Scholar Rock, an estimated $38.3M trimmed.

  • Samsara BioCapital's largest Q4 2024 buy was Septerna Inc: 2,768,520 shares worth $63.4M.
  • Samsara BioCapital added most to Neurogene in Q4 2024, an estimated $16.7M increase.
  • Samsara BioCapital's biggest Q4 2024 reduction was Scholar Rock, cutting an estimated $38.3M.
  • Samsara BioCapital fully exited Syros Pharmaceuticals, Inc. Common Stock in Q4 2024, selling an estimated $3.84M.
  • Samsara BioCapital's ten largest holdings make up 82% of its $729M portfolio in Q4 2024.
  • Samsara BioCapital opened 5 new positions and closed 4 in Q4 2024.
  • Samsara BioCapital's portfolio value rose 40% quarter-over-quarter to $729M.

Based on Samsara BioCapital's 13F filing for Q4 2024, filed 14 Feb 2025.